Journal article
Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer
WL Yang, A Gentry-Maharaj, A Simmons, A Ryan, EO Fourkala, Z Lu, KA Baggerly, Y Zhao, KH Lu, D Bowtell, I Jacobs, SJ Skates, WW He, U Menon, RC Bast
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017
Abstract
Purpose: The TP53 tumor-suppressor gene is mutated in >95% of high-grade serous ovarian cancers. Detecting an autologous antibody response to TP53 that might improve early detection. Experimental Design: An immunoassay was developed to measure TP53 autoantibody in sera from 378 cases of invasive epithelial ovarian cancer and 944 age-matched healthy controls from the United States, Australia, and the United Kingdom. Serial preclinical samples from cases and controls were also assayed from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Results: Using a cutoff value of 78 U/mL to achieve a specificity of 97.4%, TP53 autoantibody was elevated in 30% of 50 cases from MD Anderso..
View full abstractRelated Projects (2)
Grants
Awarded by U.S. Department of Health and Human Services
Funding Acknowledgements
This work was supported by funds from the Early Detection Research Network (5 U01 CA200462-02) and the MD Anderson Ovarian SPORE (P50 CA83639), National Cancer Institute, Department of Health and Human Services; the Cancer Prevention Research Institute of Texas (RP160145); Golfer's Against Cancer, the Mossy Foundation, the Roberson Endowment, National Foundation for Cancer Research; UT MD Anderson Women's Moon Shot; and generous donations from Stuart and Gaye Lynn Zarrow. The UT MD Anderson Cancer Center Odyssey Program provided support (to W.-L. Yang), the Theodore N. Law Endowment for Scientific Achievement (to W.-L. Yang); the Clyde H. Wright Memorial Fund (to W.-L. Yang) and Bristol-Myers Squibb Award in Clinical Research (to W.-L. Yang). S.J. Skates received additional support from the NCI Early Detection Research Network (CA152990). UKCTOCS was core funded by the Medical Research Council, Cancer Research UK, and the Department of Health with additional support from the Eve Appeal, Special Trustees of Bart's and the London, and Special Trustees of UCLH and supported by researchers at the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AOCSwas supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania, and the National Health and Medical Research Council of Australia (NHMRC; ID400413, ID400281). The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, the Peter MacCallum Cancer Centre Foundation, Ovarian Cancer Australia and Ovarian Cancer Action (UK).